Axsome COO Buys 19,663 RSUs at 52‑Week Low, Signaling Long‑Term Confidence in Trial‑Driven Growth
Axsome COO buys RSUs amid price dip—inside look at insider confidence, long‑term plans and what it means for investors.
3 minutes to read
Axsome Therapeutics Inc
Axsome Insider Mark Buys 72,140 Shares in Bold Bet on Therapy Pipeline, Despite Recent Price Dip
Insider buying boosts optimism for Axsome’s pipeline, as Mark Coleman’s 6,250‑share purchase signals confidence in commercial growth and Phase 3 trials.
2 minutes to read
Axsome Insider Mark Doubling Stake in 12,485-Share Buy, Betting on Future Breakthroughs Despite Volatile 52‑Week Low
Axsome insider buy signals confidence amid volatility—12,485 new shares at $4.95 could hint at a rebound after a 52‑week low.
3 minutes to read
Axsome CFO’s Low‑Price Stock Buy‑Sell Blitz Signals Insider Confidence Ahead of 21% Monthly Surge
Axsome CFO’s 12,000‑share buy at $3.50 and sell at $187.92 signals strong insider confidence, highlighting potential upside as the company hits clinical milestones.
3 minutes to read
Axsome CEO Herriot’s $13 M “buy‑sell” spree underscores bullish confidence amid FDA priority review and analyst upgrades.
CEO Tabuteau Herriot’s 2026 option‑exercise strategy shows Axsome’s leadership confident in its pain‑relief pipeline, boosting investor sentiment.
4 minutes to read